Those newly prescribed SGLT2 inhibitors had higher rates of heart and kidney conditions than those newly prescribed GLP-1 receptor agonists (eg, heart failure, 16.6% vs
We'll cover all of them
971 With the help of glucose transporter 1 on the surface of the BBB, glucose-modified GluAC4A is transported into the brain, achieving targeted drug delivery across the BBB
215 Astragalus inhibits ferroptosis in synovial cells and exerts a protective effect through activation of the SLC7A11/GPX4 axis

these results presented in supplementary table 4 Sample size: Using certain assumptions and previously validated methods, it was determined that a sample size of 516 would provide 90% power to detect a 4.1 mean difference in change in KCCQ-CSS and 99% power to detect a 9.9% mean difference in change in body weight Alpha of 0.05 was split between the two primary endpoints, 0.04 for KCCQ-CSS and 0.01 for body weight Primary analysis model for the dual primary endpoints is a linear regression analysis of covariance Missing data points filled using an established and previously described 2 imputation modelthat uses baseline characteristics, prior endpoint data, and group data to produce an unfavorable value Statistical testing hierarchy Used treatment policy estimand results Confirmatory secondary endpoints were meant to represent the overall clinical benefit/harm of the intervention

However, its safety profile is well-understood from clinical trials (in both women and men) and years of research